罗欣药业: 关于合计持股5%以上股东协议转让公司部分股份进展暨签署补充协议的公告

Group 1 - The announcement details the progress of a share transfer agreement involving major shareholders of Luoxin Pharmaceutical Group Co., Ltd, specifically Chengdu De Yi Xin Hua Equity Investment Partnership and Karamay De Yi Heng Jia Equity Investment Partnership [1][2] - Chengdu De Yi Xin Hua plans to transfer 18,589,668 unrestricted circulating shares, while Karamay De Yi Heng Jia intends to transfer 35,789,757 unrestricted circulating shares to Shanghai Zhong Jue Private Fund Management Co., Ltd, resulting in a total transfer of 54,379,425 shares, which represents 5% of the company's total share capital [3][5] - A supplementary agreement has been signed, stipulating that the transferee, Zhong Jue Fund, commits not to transfer the acquired shares for 18 months following the completion of the share transfer [5][6] Group 2 - The agreement ensures compliance with relevant laws and regulations, confirming that the transfer does not harm the interests of the company or its shareholders, particularly minority shareholders [6] - The completion of the share transfer is subject to regulatory approval and may face uncertainties, which investors are advised to consider [6]